S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NASDAQ:VTGN - Vistagen Therapeutics Stock Price, Forecast & News

$0.69
+0.03 (+4.57 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$0.65
Now: $0.69
$0.69
50-Day Range
$0.65
MA: $0.72
$0.80
52-Week Range
$0.29
Now: $0.69
$1.51
Volume91,263 shs
Average Volume260,232 shs
Market Capitalization$32.92 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.43
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.25 million
Book Value($0.13) per share

Profitability

Net Income$-24,590,000.00

Miscellaneous

Employees9
Market Cap$32.92 million
Next Earnings Date6/23/2020 (Estimated)
OptionableNot Optionable

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.


Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics Inc (NASDAQ:VTGN) announced its earnings results on Thursday, February, 13th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.08. View Vistagen Therapeutics' Earnings History.

When is Vistagen Therapeutics' next earnings date?

Vistagen Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, June 23rd 2020. View Earnings Estimates for Vistagen Therapeutics.

What price target have analysts set for VTGN?

3 Wall Street analysts have issued 12-month price objectives for Vistagen Therapeutics' shares. Their forecasts range from $0.70 to $4.00. On average, they anticipate Vistagen Therapeutics' stock price to reach $2.35 in the next twelve months. This suggests a possible upside of 242.4% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics.

What is the consensus analysts' recommendation for Vistagen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vistagen Therapeutics.

What are Wall Street analysts saying about Vistagen Therapeutics stock?

Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
  • 1. Chardan Capital analysts commented, "We transfer coverage of VTGN to better align coverage with current focus areas of analysts. We downgrade to $0.70 price target. We believe that VistaGen Therapeutics now faces an uphill battle after a setback in AV-101 development, one that to us will not be aided by recent pipeline acquisitions. VistaGen announced the NIMH-sponsored phase II trial (NCT02484456) of AV-101 in treatment resistant depression (TRD) missed its primary endpoint of change from baseline on the Scale (HDRS). 19-patient study showed no separation of AV-101 from placebo. The NIMH trial evaluated AV-101 as a monotherapy, whereas VistaGen is positioning AV-101 as an adjunct therapy. However, to us a clinical trial failure does not bode well for the success for AV-101." (7/22/2019)
  • 2. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/11/2019)

Has Vistagen Therapeutics been receiving favorable news coverage?

Headlines about VTGN stock have trended negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vistagen Therapeutics earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Vistagen Therapeutics.

Are investors shorting Vistagen Therapeutics?

Vistagen Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,640,000 shares, a drop of 8.3% from the January 15th total of 2,880,000 shares. Based on an average daily volume of 817,900 shares, the days-to-cover ratio is currently 3.2 days. Currently, 7.0% of the company's shares are sold short. View Vistagen Therapeutics' Current Options Chain.

Who are some of Vistagen Therapeutics' key competitors?

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Matinas BioPharma (MTNB), vTv Therapeutics (VTVT), Lithium Americas (LAC), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP) and Yamana Gold (AUY).

Who are Vistagen Therapeutics' key executives?

Vistagen Therapeutics' management team includes the folowing people:
  • Mr. Shawn K. Singh, CEO & Director (Age 56)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)
  • Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 64)

Who are Vistagen Therapeutics' major shareholders?

Vistagen Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Blair William & Co. IL (0.12%). Company insiders that own Vistagen Therapeutics stock include H Ralph Snodgrass and Jon S Saxe. View Institutional Ownership Trends for Vistagen Therapeutics.

Which institutional investors are selling Vistagen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL. View Insider Buying and Selling for Vistagen Therapeutics.

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vistagen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.69.

How big of a company is Vistagen Therapeutics?

Vistagen Therapeutics has a market capitalization of $32.92 million and generates $1.25 million in revenue each year. The company earns $-24,590,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.View Additional Information About Vistagen Therapeutics.

What is Vistagen Therapeutics' official website?

The official website for Vistagen Therapeutics is http://www.vistagen.com/.

How can I contact Vistagen Therapeutics?

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]


MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)

Community Ranking:  3.0 out of 5 (star star)
Outperform Votes:  244 (Thanks for Voting!)
Underperform Votes:  169 (Thanks for Voting!)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel